2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2677

Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in Patients with Rheumatoid Arthritis
Abstract Number: 2015

Targeting Non-Canonical NF-Kappa B Signaling Inhibits Angiogenesis in a Novel 3D Model of Rheumatoid Arthritis Synovial Angiogenesis
Abstract Number: 2546

Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Abstract Number: 2561

TAS5315, a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Abstract Number: 535

Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis
Abstract Number: 2080

Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers
Abstract Number: 2222

Teaching Rheumatology in Undergraduate Medical Education: What Are the Students Saying?
Abstract Number: 2230

Teaching the Teachers: Report of an Effective Mixed-Method Course Training Clinical Educators to Provide Instruction in Musculoskeletal Care to Other Providers and Learners in Primary Care
Abstract Number: 2495

Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 2496

Telerheumatology: A Technology Not Appropriate for All
Abstract Number: 1606

Telomere Damage in Rheumatoid Arthritis
Abstract Number: 1593

Telomere Length and Cardiovascular Risk in Rheumatoid Arthritis
Abstract Number: 1534

Temporal Trends and Outcomes of Acute Myocardial Infarction in Rheumatoid Arthritis Hospitalizations
Abstract Number: 1066

Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations
Abstract Number: 2103

Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].